Anti-thrombotic effects of selective estrogen receptor modulator tamoxifen

Nayak, M. K. ; Singh, S. K. ; Roy, A. ; Prakash, V. ; Kumar, A. ; Dash, D. (2011) Anti-thrombotic effects of selective estrogen receptor modulator tamoxifen Thrombosis and Haemostasis, 106 (4). pp. 624-635. ISSN 0340-6245

Full text not available from this repository.

Official URL:

Related URL:


Summary: Tamoxifen is a known anti-cancer drug and established estrogen receptor modulator. Few clinical studies have earlier implicated the drug in thrombotic complications attributable to lower anti-thrombin and protein S levels in plasma. However, action of tamoxifen on platelet signalling machinery has not been elucidated in detail. In the present report we show that tamoxifen is endowed with significant inhibitory property against human platelet aggregation. From a series of in vivo and in vitro studies tamoxifen was found to inhibit almost all platelet functions, prolong tail bleeding time in mouse and profoundly prevent thrombus formation at injured arterial wall in mice, as well as on collagen matrix perfused with platelet-rich plasma under arterial shear against the vehicle dimethylsulfoxide (DMSO). These findings strongly suggest that tamoxifen significantly downregulates platelet responses and holds potential as a promising anti-platelet / anti-thrombotic agent.

Item Type:Article
Source:Copyright of this article belongs to Schattauer.
Keywords:Thrombosis; Platelet Aggregation; Estrogen Receptor; Antiplatelet Drug; Selective Estrogen Receptor Modulators (SERM)
ID Code:101238
Deposited On:04 Feb 2017 17:24
Last Modified:04 Feb 2017 17:24

Repository Staff Only: item control page